The ambition is to start deliveries of Gilead Sciences’ lenacapavir on that timeline, said Hui Yang, head of supply operations at the Global Fund to Fight AIDS, Tuberculosis and Malaria.

The approval of new therapies like Sunlenca (lenacapavir) has further strengthened the franchise. Gilead projects HIV sales to grow 5% in 2024. The successful development and potential approval of ...

The ambition is to start deliveries of Gilead Sciences’(GILD.O) lenacapavir on that timeline, said Hui Yang, head of supply operations at the Global Fund to Fight AIDS, Tuberculosis and Malaria.

Gilead Sciences is seeking approval from the USFDA and the World Health Organization (WHO) for a global rollout of its injectable drug version. A new variant of Lenacapavir, a drug used to treat ...

Lenacapavir, a preventive HIV drug, could become accessible in low-income countries by 2026. Efforts spearheaded by global health organizations aim to ensure timely access without delays in regulatory ...

Gilead's stock has surged due to successful launches of Livdelzi for PBC and promising developments in lenacapavir for HIV prevention. Livdelzi's approval and strong market potential, combined ...

It is a fictional representation created for illustrative purposes only. A new HIV preventive drug, lenacapavir, might become available in financially constrained regions by late 2025. This was ...

The ambition is to start deliveries of Gilead Sciences’ lenacapavir on that timeline, said Hui Yang, head of supply operations at the Global Fund to Fight AIDS, Tuberculosis and Malaria.